Analyzing Biomed Realty Trust (BMR) & Its Competitors

Biomed Realty Trust (NYSE: BMR) is one of 74 publicly-traded companies in the “Commercial REITs” industry, but how does it compare to its competitors? We will compare Biomed Realty Trust to similar companies based on the strength of its dividends, institutional ownership, valuation, profitability, risk, analyst recommendations and earnings.

Analyst Recommendations

This is a summary of recent recommendations for Biomed Realty Trust and its competitors, as reported by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Biomed Realty Trust 0 0 0 0 N/A
Biomed Realty Trust Competitors 634 2585 2154 24 2.29

As a group, “Commercial REITs” companies have a potential upside of 7.20%. Given Biomed Realty Trust’s competitors higher possible upside, analysts clearly believe Biomed Realty Trust has less favorable growth aspects than its competitors.


Biomed Realty Trust pays an annual dividend of $1.04 per share and has a dividend yield of 4.4%. Biomed Realty Trust pays out 100.0% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. As a group, “Commercial REITs” companies pay a dividend yield of 3.9% and pay out 92.3% of their earnings in the form of a dividend. Biomed Realty Trust has raised its dividend for 7 consecutive years.


This table compares Biomed Realty Trust and its competitors’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Biomed Realty Trust 18.98% 3.73% 2.07%
Biomed Realty Trust Competitors 52.62% 6.78% 3.85%

Earnings & Valuation

This table compares Biomed Realty Trust and its competitors gross revenue, earnings per share and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Biomed Realty Trust N/A N/A 22.89
Biomed Realty Trust Competitors $536.81 million $100.12 million 397.11

Biomed Realty Trust’s competitors have higher revenue and earnings than Biomed Realty Trust. Biomed Realty Trust is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Insider & Institutional Ownership

73.2% of shares of all “Commercial REITs” companies are owned by institutional investors. 7.3% of shares of all “Commercial REITs” companies are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.


Biomed Realty Trust competitors beat Biomed Realty Trust on 8 of the 9 factors compared.

About Biomed Realty Trust

BioMed Realty Trust, Inc. operates as a real estate investment trust (REIT). The Company is the parent company and general partner of BioMed Realty, L.P. The Company owns, acquires, develops, redevelops, leases and manages laboratory and office space for the life science industry. The Company’s tenants primarily include biotechnology and pharmaceutical companies, scientific research institutions, government agencies and other entities involved in the life science industry. The Company’s properties are located in markets, which has centers for scientific research, including Boston, San Francisco, San Diego, Maryland, New York, New Jersey, Pennsylvania, North Carolina, Seattle, Cambridge (the United Kingdom) and research parks located near or adjacent to universities and their related medical systems. The Company owns interests in properties comprising approximately 17.5 million rentable square feet.

Receive News & Ratings for Biomed Realty Trust Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biomed Realty Trust Inc and related companies with's FREE daily email newsletter.

Leave a Reply